Can-Fite BioPharma (CANF) Total Current Liabilities (2014 - 2025)
Can-Fite BioPharma's (CANF) quarterly Total Current Liabilities came in at $2.7 million in Q4 2025, up 33.09% YoY from $2.1 million in Q4 2024, and up 28.82% on a QoQ basis from $2.1 million in Q2 2025.
Can-Fite BioPharma (CANF) Total Current Liabilities (2014 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 12 years of Total Current Liabilities data on file, last reported at $2.7 million in Q4 2025.
- Quarterly Total Current Liabilities rose 33.09% year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 million (up 33.09% YoY) and the FY2025 annual result came in at $2.7 million, up 33.09% from the prior year.
- Total Current Liabilities rose to $2.7 million in Q4 2025, from $2.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.9 million in Q1 2022 to a low of $2.0 million in Q2 2024.
- A 5-year average of $2.4 million and a median of $2.2 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities soared 115.13% — and 2023, when it fell 20.96%.
- Tracing CANF's Total Current Liabilities over 5 years: stood at $2.7 million in 2021, then dropped by 8.35% to $2.5 million in 2022, then retreated by 19.26% to $2.0 million in 2023, then grew by 1.58% to $2.1 million in 2024, then jumped by 33.09% to $2.7 million in 2025.
- The last three Total Current Liabilities figures came in at $2.7 million (Q4 2025), $2.1 million (Q2 2025), and $2.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | 2.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.73 Mn |
| Jun 30, 2025 | 2.12 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Dec 31, 2023 | 2.02 Mn |
| Sep 30, 2023 | 2.21 Mn |
| Jun 30, 2023 | 2.23 Mn |
| Mar 31, 2023 | 2.89 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 2.15 Mn |
| Mar 31, 2022 | 2.90 Mn |
| Dec 31, 2021 | 2.73 Mn |
| Sep 30, 2021 | 2.15 Mn |
| Jun 30, 2021 | 2.36 Mn |
| Mar 31, 2021 | 2.06 Mn |
| Dec 31, 2020 | 1.27 Mn |
| Jun 30, 2020 | 1.50 Mn |
| Dec 31, 2019 | 3.27 Mn |
| Sep 30, 2019 | 3.13 Mn |